• Kiora Pharmaceuticals Inc KPRX.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -81 cents. The lone analyst forecast for the quarter was for a loss of 67 cents per share.

• Reported revenue was zero​; analysts expected $1.50 million.

• Kiora Pharmaceuticals Inc's reported EPS for the quarter was 1 cent​.

• The company reported a quarterly loss of $6.52 million.

• Kiora Pharmaceuticals Inc shares had risen by 4.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 9.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $12.00, about 82.8% above its last closing price of $2.06

This summary was machine generated from LSEG data March 25 at 02:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)